Role of the tripartite motif protein 27 in cancer development

Journal of the National Cancer Institute

Volumn 104, Issue 12, 2012, Pages 941-952

  Zoumpoulidou, Georgia ^a,b   Broceño, Cristina ^b,c   Li, He ^b,d   Bird, Demelza ^b,e   Thomas, George ^b,d   Mittnacht, Sibylle ^a,b,f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY RNA; DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; REPRESSOR PROTEIN; RETINOBLASTOMA ASSOCIATED PROTEIN 1; RETINOBLASTOMA PROTEIN; TRIPARTITE MOTIF PROTEIN 27; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; CELL AGING; CELL PROLIFERATION; CELL STRUCTURE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE DELETION; GENE EXPRESSION PROFILING; HUMAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SKIN CANCER; SKIN CARCINOGENESIS; TRANSCRIPTION REGULATION;

CELL AGING; CELL PROLIFERATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; DNA-BINDING PROTEINS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RESEARCH DESIGN; RETINOBLASTOMA PROTEIN; RNA, COMPLEMENTARY; SKIN NEOPLASMS; UP-REGULATION;

EID: 84864128565     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs224     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144 (5): 646-674.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100 (1): 57-70. (Pubitemid 30046295)
3. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985; 42 (2): 581-588. (Pubitemid 16091150)
4. Hasegawa N, Iwashita T, Asai N, et al. A RING fi nger motif regulates transforming activity of the rfp/ret fusion gene. Biochem Biophys Res Commun. 1996; 225 (2): 627-631. (Pubitemid 26355649)
5. Tezel G, Nagasaka T, Shimono Y, et al. Differential expression of RET fi nger protein in testicular germ cell tumors. Pathol Int. 2002; 52 (10): 623-627. (Pubitemid 35365677)
6. Tsukamoto H, Kato T, Enomoto A, et al. Expression of Ret fi nger protein correlates with outcomes in endometrial cancer. Cancer Sci. 2009; 100 (10): 1895-1901.
7. Tezel GG, Uner A, Yildiz I, et al. RET fi nger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression. Pathol Res Pract. 2009; 205 (6): 403-408.
8. McNab FW, Rajsbaum R, Stoye JP, et al. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol. 2011; 23 (1): 46-56.
9. Skarnes WC, von Melchner H, Wurst W, et al. A public gene trap resource for mouse functional genomics. Nat Genet. 2004; 36 (6): 543-544. (Pubitemid 38715972)
10. Shieh PB, Kudryashova E, Spencer MJ. Limb-girdle muscular dystrophy 2H and the role of TRIM32. Handb Clin Neurol. 2011; 101 : 125-133.
11. Munir M. TRIM proteins: another class of viral victims. Sci Signal. 2010; 3 (118): jc2.
12. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011; 11 (11): 792-804.
13. Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene. 2011; 30 (9): 1108-1116.
14. Matsuura T, Shimono Y, Kawai K, et al. PIAS proteins are involved in the SUMO-1 modifi cation, intracellular translocation and transcriptional repressive activity of RET fi nger protein. Exp Cell Res. 2005; 308 (1): 65-77. (Pubitemid 40984762)
15. Meroni G, Diez-Roux G. TRIM/RBCC, a novel class of 'single protein RING fi nger' E3 ubiquitin ligases. Bioessays. 2005; 27 (11): 1147-1157. (Pubitemid 43076141)
16. Gillot I, Matthews C, Puel D, et al. Ret fi nger protein: an E3 ubiquitin ligase juxtaposed to the XY body in meiosis. Int J Cell Biol. 2009; 2009 : 524858.
17. Napolitano LM, Jaffray EG, Hay RT, et al. Functional interactions between ubiquitin E2 enzymes and TRIM proteins. Biochem J. 2011; 434 (2): 309-319.
18. Shimono Y, Murakami H, Hasegawa Y, et al. RET fi nger protein is a transcriptional repressor and interacts with enhancer of polycomb that has dual transcriptional functions. J Biol Chem. 2000; 275 (50): 39411-39419. (Pubitemid 32058965)
19. Krutzfeldt M, Ellis M, Weekes DB, et al. Selective ablation of retinoblastoma protein function by the RET fi nger protein. Mol Cel.l. 2005; 18 (2): 213-224.
20. Zha J, Han KJ, Xu LG, et al. The Ret fi nger protein inhibits signaling mediated by the noncanonical and canonical IkappaB kinase family members . J Immunol. 2006; 176 (2): 1072-1080. (Pubitemid 43099708)
21. Abel EL, Angel JM, Kiguchi K, et al. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc. 2009; 4 (9): 1350-1362.
22. Alani RM, Young AZ, Shiffl ett CB. Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA. 2001; 98 (14): 7812-7816. (Pubitemid 32642643)
23. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol. 1963; 17 (2): 299-313.
24. Dimri GP, Lee X, Basile G, et al. A biomarker that identifi es senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995; 92 (20): 9363-9367.
25. Jacks T, Fazeli A, Schmitt EM, et al. Effects of an Rb mutation in the mouse. Nature. 1992; 359 (6393): 295-300.
26. Kato T, Shimono Y, Hasegawa M, et al. Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress. Cancer Res. 2009; 69 (8): 3597-3604.
27. Kemp CJ. Multistep skin cancer in mice as a model to study the evolution of cancer cells. Semin Cancer Biol. 2005; 15 (6): 460-473. (Pubitemid 41318046)
28. Boutwell RK, Verma AK, Ashendel CL, et al. Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis. Carcinog Compr Surv. 1982; 7 : 1-12.
29. Cao T, Shannon M, Handel MA, et al. Mouse ret fi nger protein (rfp) proto-oncogene is expressed at specifi c stages of mouse spermatogenesis. Dev Genet. 1996; 19 (4): 309-320. (Pubitemid 27061141)
30. Lapouge G, Youssef KK, Vokaer B, et al. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci USA. 2011; 108 (18): 7431-7436.
31. Sun H, Taneja R. Analysis of transformation and tumorigenicity using mouse embryonic fi broblast cells. Methods Mol Biol. 2007; 383 : 303-310.
32. Hayfl ick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961; 25 : 585-621.
33. Sherr CJ, DePinho RA. Cellular senescence: mitotic clock or culture shock? Cell. 2000; 102 (4): 407-410.
34. Zhang H. Molecular signaling and genetic pathways of senescence: its role in tumorigenesis and aging. J Cell Physiol. 2007; 210 (3): 567-574. (Pubitemid 46188287)
35. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005; 37 (5): 961-976. (Pubitemid 40311739)
36. Blagosklonny MV. Cell senescence: hypertrophic arrest beyond the restriction point. J Cell Physiol. 2006; 209 (3): 592-597. (Pubitemid 44665674)
37. Cristofalo VJ, Lorenzini A, Allen RG, et al. Replicative senescence: a critical review. Mech Ageing Dev. 2004; 125 (10-11): 827-848. (Pubitemid 39485238)
38. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88 (5): 593-602. (Pubitemid 27152402)
39. Weinberg RA. The cat and mouse games that genes, viruses, and cells play. Cell. 1997; 88 (5): 573-575. (Pubitemid 27152398)
40. Peeper DS, Dannenberg JH, Douma S, et al. Escape from premature senescence is not suffi cient for oncogenic transformation by Ras. Nat Cell Biol. 2001; 3 (2): 198-203. (Pubitemid 32118374)
41. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005; 436 (7051): 642. (Pubitemid 41117258)
42. Dimri GP. What has senescence got to do with cancer? Cancer Cell. 2005; 7 (6): 505-512. (Pubitemid 40799244)
43. Chandeck C, Mooi WJ. Oncogene-induced cellular senescence. Adv Anat Pathol. 2010; 17 (1): 42-48.
44. Quintanilla M, Brown K, Ramsden M, et al. Carcinogen-specifi c mutation and amplifi cation of Ha-ras during mouse skin carcinogenesis. Nature. 1986; 322 (6074): 78-80. (Pubitemid 16061512)
45. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 1998; 395 (6698): 125-126. (Pubitemid 28425643)
46. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004; 23 (16): 2919-2933. (Pubitemid 38638853)
47. Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence . Nat Cell Biol. 2006; 8 (11): 1291-1297. (Pubitemid 44660595)
48. Chicas A, Wang X, Zhang C, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell. 2010; 17 (4): 376-387.
49. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005; 120 (4): 513-522. (Pubitemid 40269765)
50. Lu T, Finkel T. Free radicals and senescence. Exp Cell Res. 2008; 314 (9): 1918-1922.